Buy SNY by Jun 15, 2027.

Sanofi share has been flat for a decade, despite continuously increasing dividend every year. They also have the fourth-biggest selling drug in the world: Dupixent, which they co-developed and co-owned with Regeneron. They make €47B in revenue last year, €19B from Dupixent. But Dupixent is losing its US exclusivity in the US on March 2031, and this is primarily why investors are discounting the company. They are trading at \~9x forward earnings and \~12x trailing earnings (or \~19x on some …